Aquestive Therapeutics issued the following announcement on Jan. 25.
Aquestive Therapeutics, Inc. (Nasdaq: AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems, announced that the U.S. District Court for the District of New Jersey has granted a temporary restraining order (TRO) that enjoins Alvogen from initiating any launch activities related to its generic buprenorphine/naloxone sublingual film. This TRO will remain in place pending a hearing on the preliminary injunction (PI) motion previously filed by Aquestive and Indivior PLC (LON: INDV). The hearing on the PI motion is scheduled with the District Court on February 7, 2019.
The '305 patent for SUBOXONE® Sublingual Film, held by Aquestive and Indivior, remains the subject of ongoing patent infringement litigation regarding generic buprenorphine/naloxone sublingual films.
"We are pleased that the Court has granted our request for a temporary restraining order. We are continuing to work with Indivior to assert and protect our intellectual property embedded in SUBOXONE," said Keith Kendall, CEO of Aquestive Therapeutics. "Despite multiple alternative products in the market over the last several years, SUBOXONE Sublingual Film remains the market leader, and we are confident that it will continue to thrive based on the proven track record the product has in addressing patient needs and preferences for treatment."
Original source can be found here.